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Background: Cognitive impairment in Parkinson’s disease (PD) is common and recent 
studies have focused on addressing the most suitable screening tool for its 
assessment. MMSE is commonly used in clinical practice and longitudinal studies 
found a relationship between the MMSE pentagon copying item and progression to 
dementia, but its neuroanatomical correlates have been poorly investigated. The aim of 
this study is to investigate the MRI structural correlates of the global MMSE and the 
pentagon item scores in PD patients in the absence of dementia. 
Methods: We selected a sample of 92 PD patients and 36 controls. MMSE was used 
as a global measure of cognitive status, and the pentagon copying test as a measure 
of visuospatial performance. FreeSurfer software was used to assess intergroup 
differences in cortical thickness (CTh) and global atrophy measures, as well as their 
relationship with cognitive performance. 
Results: Compared to controls, patients showed significant differences in measures of 
global atrophy, which correlated with performance on MMSE and the pentagon item. 
Regional differences in CTh were seen between PD patients and controls bilaterally in 
the temporo-parietal-occipital region. Patients with impaired performance compared 
with those of normal performance also showed CTh reductions in these regions.  
Conclusion: Our results suggest MMSE and the pentagon item reflect brain changes 
which at a regional level involve mainly posterior regions. Correlates of the pentagon 
item were seen in the same regions where PD patients exhibited significant thinning, 






Cognitive impairment is a frequent [1] and important non-motor symptom in Parkinson’s 
disease (PD) [2, 3], with a significant impact on quality of life [4]. Over time, 
approximately 80% of patients become demented [5]. The Mini-Mental State 
Examination (MMSE) is the cognitive screening tool most frequently used to assess 
global cognitive status in degenerative illnesses [6]. Rate of change of MMSE scores in 
PD ranged from 1.4 to 6.8 points per year [1]. However, the MMSE is not considered 
as a suitable screening tool to assess cognitive dysfunctions in PD, because it does not 
fully address executive functions [6], which is one of the domains usually impaired in 
this disease [2]. Therefore, other screening tests have been proposed as alternatives, 
such as the Montreal Cognitive Assessment (MoCA) [7].  
Although the MMSE is not commonly used as a single screening tool in PD, scores 
below the cut-off point of 26 are used as a criterion in the identification of dementia in 
PD [8]. Despite the broad criticism associated with the MMSE, the pentagon item 
raised interest in clinical settings because of a population-based longitudinal study 
where it was found to be predictive of dementia in PD [1, 9, 10], suggesting that the 
dementing process is heralded by posterior cortical based cognitive deficits [1, 9, 10]. 
Magnetic resonance imaging (MRI) volumetric research has also shown that PD 
patients’ MMSE scores significantly correlate with measures of global atrophy such as 
ventricular volume [11]. The correlates with regional gray matter reductions were 
observed in temporo-parietal regions in voxel-based morphometry studies [12] and also 
involved frontal regions using cortical thickness (CTh) analyses [13]. A recent study 
using an ROI-based analysis in non-demented PD patients has shown that the 
pentagon copying test significantly correlates with volumetric decreases in cortical 
regions, such as right supplementary motor area, left rostral middle frontal cortex, pars 
triangularis and left cuneus [14]. However, to our knowledge, there are no previous 
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studies specifically assessing the correlations between pentagon copying test and 
whole-brain CTh.   
Therefore, the aims of this study were 1) to investigate the MRI structural correlates of 
the MMSE global scores and the pentagon item and 2) to identify whether impairment 




The cohort of this study consisted of 121 PD patients consecutively recruited from an 
outpatient movement disorders clinic (Parkinson’s disease and Movement Disorders 
Unit, Service of Neurology, Hospital Clínic, Barcelona, Spain) from September 2010 to 
March 2012. Forty-one healthy subjects were recruited from the Institut de l’Envelliment 
(Barcelona, Spain) and were matched for age, sex and years of education to their 
patients peers. This study was approved by the ethics committee of the University of 
Barcelona; all subjects agreed to participate voluntarily and written informed consent 
was obtained after full explanation of the procedures. 
Inclusion criteria for participants consisted of fulfilling the diagnostic criteria for PD 
established by the UK PD Society Brain Bank [15]. Exclusion criteria consisted of: [1] 
presence of dementia according to the Movement Disorders Society criteria [8], [2] 
Hoehn and Yahr (H&Y) scale score >3, [3] juvenile-onset PD, [4] presence of 
psychiatric and/or neurologic comorbidity, [5] low global IQ score estimated by the 
Vocabulary subtest of the Wechsler Adult Intelligence Scale, 3rd edition (Scalar score 
≤7 points) , [6] MMSE score ≤25, [7] claustrophobia, [8] imaging findings on MRI not 
compatible with PD and [9] MRI artifacts. Levodopa equivalent daily dose (LEDD) was 
calculated as suggested by Tomlinson et al. [16]. 
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Ninety-two PD patients and 36 healthy volunteers were finally selected. Twelve 
patients and eight controls were excluded as they fulfilled criteria for dementia or other 
neurological disease, six PD patients for psychiatric comorbidity, one PD patient who 
scored higher than 3 on the H&Y scale, one PD patient who presented with juvenile-
onset PD, three PD patients and one control who had low global IQ scores, two PD 
patients for claustrophobia, two PD patients and two controls were excluded because 
of missing tests used in this study and two controls and two PD patients due to MRI 
artefacts (demographic and clinical data of patients and healthy controls included in 
study sample are summarized in Table 1). Excluded patients did not differ from final PD 
participants in terms of demographics and clinical variables.  
 
Cognitive status assessment 
The screening test MMSE was used as a global measure of cognitive status. We used 
two additional grading measurements of the pentagon item: the scoring system of the 
Modified Mini-Mental State (3MS), a modified MMSE grading system that provides a 
quantitative, wide-range scoring measurement system; and the simple scoring system 
(SSS) used by Williams-Gray et al., because of its demonstrated value in predicting 
conversion to dementia in PD patients [1, 9, 10].  
According to the original scoring criteria [17], the pentagon item is considered correct if 
5 angles are present in each pentagon and 2 are intersecting. Possible scores are 0 
and 1. In the 3MS version, scores range from 0 to 10. Up to 4 points are given for each 
pentagon and up 2 points for the intersecting quadrilateral. Four points are given to 
each pentagon when it has 5 approximately equal sides, whereas 3 points account for 
5 sides but unequal (>2:1). Lower scores are given when another enclosed figure is 
drawn (2 points), or 2 or more lines (1 point); less than 2 lines account for 0 points. The 
simple scoring system used by Williams-Gray et al. [1, 9, 10] grades 2 points to those 
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pentagons that meet the original criteria, whereas 1 point is given for those that meet 
the “relaxed criteria”, in which there must be two figures that seem to be intersecting, at 
least one of them having 5 angles. Zero points are given to less accurate copies, i.e., to 
those figures in which no pentagon exhibits 5 angles and/or there is no intersection 
present (see Figure 1AS for drawing and grading scores examples). For correlation 
analyses purposes we scored the test as 1, 2 and 3.  
  
MRI Acquisition 
Magnetic resonance images were acquired with a 3T scanner (MAGNETOM Trio, 
Siemens, Germany). The scanning protocol included high-resolution 3-dimensional T1-
weighted images acquired in the sagittal plane (TR=2300 ms, TE=2.98 ms, TI 900 ms, 
240 slices, FOV=256 mm; matrix size=256x256; 1 mm isotropic voxel) and an axial 
FLAIR sequence (TR=9000 ms, TE=96 ms).  
 
Cortical Thickness Analysis 
FreeSurfer software (version 5.1; available at http://surfer.nmr.harvard.edu) was used 
to obtain CTh and whole brain measurements of brain atrophy. The cortical surface 3D 
model of CTh is created using intensity and continuity information, as described in 
detail by authors [18]. Independent steps are performed in the initial preprocessing of 
images for each subject: removal of non-brain tissue, automated Talairach 
transformation, intensity normalization [19], tessellation of the gray matter / white 
matter boundary, automated topology correction [20] and accurate surface deformation 
to optimally place the gray matter / white matter and gray matter / cerebrospinal fluid 
(CSF) boundaries [18]. The resulting representation of CTh is calculated as the 
distance between white and gray matter surfaces at each vertex of the reconstructed 
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cortical mantle [19]. In our study, results for each subject were carefully visually 
inspected to ensure accuracy of registration, skull stripping, segmentation, and cortical 
surface reconstruction. Maps were smoothed using a circularly symmetric Gaussian 
kernel across the surface with a full width at half maximum (FWHM) of 15 mm. 
Comparisons between groups and CTh correlations were assessed using vertex-by-
vertex general linear model, including CTh as a dependent factor and cognitive scores 
as independent factors. In the PD patient group, the vertex-by-vertex general linear 
model was used to assess the relationship between cognitive scores and CTh. Positive 
and negative associations between each test were assessed using Qdec. In order to 
avoid clusters appearing significant purely by chance (i.e., false positives), Monte Carlo 
Null-Z Simulation with 10000 iterations was applied to CTh maps to provide clusterwise 
correction for multiple comparisons and results were thresholded at a corrected p value 
of 0.05 [21].  
 
Global atrophy measures 
Mean thickness for both hemispheres was calculated ((left hemisphere thickness * left 
hemisphere surface area) + (right hemisphere thickness * right hemisphere surface 
area)) / (left hemisphere surface area + right hemisphere surface area)). Total gray 
matter and lateral ventricular volumes were obtained automatically via whole brain 
segmentation procedures performed with FreeSurfer software [22].  
 
Statistical analyses  
Statistical analyses of neuropsychological, demographic, clinical and MRI volumetric 
data variables were carried out using the statistical package SPSS-20 (2011; Armonk, 
NY: IBM Corp.). Student t tests were used to assess group differences between 
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patients and healthy subjects in clinical and neuropsychological continuous variables 
(i.e., MMSE and 3MS scoring system) and Chi square test was applied to assess group 
differences in categorical variables (i.e., sex and group). 
Group differences were assessed with Student t test statistics for mean thickness, and 
with ANCOVA including intracranial volume (ICV) as a covariate in the model for 
volumetric atrophy measures. We addressed the reliability of the scoring systems used 
with Cronbach’s α. 
Correlations between mean thickness and continuous variables were assessed with 
Pearson’s r statistics and with and Spearman’s ρ for categorical variables. Correlations 
between cognitive scores and volumetric variables were analyzed using partial 
Pearson’s r, accounting for ICV.  
 
Results  
Imaging analyses revealed that PD patients compared to controls had significant 
increases in lateral ventricle volume as well as reduction in mean CTh, but did not differ 
in global cortical gray matter volume (see Table 2).  
Regional CTh maps showed that PD patients had thickness reductions involving lateral 
and medial temporo-parieto-occipital cortices bilaterally (see Figure 1A and 
Supplementary Table 1 for details of the location and size of significant clusters).  
MMSE scores in PD patients (29.05 ± 1.1) were significantly lower than those of the 
control group (29.67 ± 0.5) (t=4.429, P<.001). Pentagon-copying scores according to 
3MS system also differed significantly (t=2.136, P=.035) between patients (9.3 ± 1.1) 





Global atrophy measures in PD patients 
MMSE correlated with mean CTh and lateral ventricular volume in PD patients. Mean 
cortical thickness and cortical gray matter volume showed significant correlations with 
3MS scores. Correlations between global atrophy measures and the simple scoring 
system were significant for mean cortical thickness but not for lateral ventricular volume 
(see Table 3). 
 
Cortical thickness in PD patients 
Patients with abnormal scores on the pentagon item according to the original criteria 
(n=15), compared with those of normal scores (n=77), had significant thickness 
reductions in the left superior temporal gyrus and precuneus bilaterally, as well as in 
the right precentral and postcentral gyri, superior parietal region and posterior cingulate 
cortex (see Figure 1B and Supplementary Table 2). PD patients’ MMSE scores 
significantly correlated with CTh in left occipital and posterior cingulate regions (see 
Figure 2A and Supplementary Table 3).  
Pentagon item scores according to 3MS showed significant correlations with CTh 
involving bilateral posterior areas, such as parietal and temporal bilateral cortex, but 
spreading also to anterior regions, including paracentral and medial frontal areas (see 
Figure 2B and Supplementary Table 3).  
The simple scoring system showed significant correlations with bilateral 
parietotemporal regions, including the left precuneus and right supramarginal, superior 
parietal, fusiform and posterior cingulate regions (see Figure 2C and Supplementary 
Table 3). There were no significant correlations between structural measures and 





In our study, non-demented PD patients showed mean CTh decreases and ventricular 
enlargement. In addition, we observed cortical thinning in bilateral posterior parieto-
temporal regions. Both MMSE and pentagon item scores correlated with measures of 
global atrophy and with regional CTh but with different extent and patterns.  
MMSE scores correlated with measures of global cerebral atrophy, namely, mean 
cortical thickness and ventricular enlargement. Our results about correlations with 
ventricular enlargement are in agreement with previous studies that tested such 
relationship with samples that included cognitively impaired patients [11]. As expected, 
the pattern of regional correlations that we have observed was less extended than that 
previously reported in samples which included demented patients [13]. We only 
obtained significant correlations in regions limited to the left hemisphere. The left 
hemisphere predominance could be due to the fact that MMSE scores include several 
verbal items [23]. MMSE decreases in PD are probably indicating evolution to 
dementia.  In this sense, Compta et al. [24] reported that Braak tau stages along with 
the parietal, cingulate, entorhinal and total cortical amyloid-B scores negatively 
correlated with MMSE scores ante-mortem, whereas such correlation was not found for 
the Lewy body score or Braak Parkinson’s disease stage. Thus, there is some 
neuropathological evidence suggesting that MMSE decreases in PD are related to 
Alzheimer’s-type pathology. 
The scores of the pentagon copying test are also reflecting the degree of diffuse 
cerebral atrophy, but have a further pattern of CTh correlations involving bilateral 
posterior temporo-parietal regions. These results are in agreement with previous 
studies performed with non-demented PD patients that focused on the correlates of 
visuospatial and visuoperceptual functions using more complex tests, such as Benton’s 
Visual Form Discrimination and Facial Recognition Test [25]. In demented PD, it has 
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been reported that visuospatial functions assessed by clock copying correlated with left 
precuneus and lingual gyrus thickness [26]. The only previous study that reported the 
anatomical correlates of the pentagon item test using ROI-based analyses also found 
correlations in medial bilateral posterior areas but also in the left anterior regions [14]; 
differences in both studies may be due to the MRI analyses and the procedures used 
to quantify the performance of the pentagon test. 
We investigated the possible differential patterns of correlations in relation to the 
cognitive measurements. Interestingly, the pentagon’s pattern of correlations observed 
was very similar to CTh reductions obtained in the comparison between PD patients 
and controls. Previous research assessing the relevance of cognitive deficits heralded 
by posterior cortical changes has evidenced that these deficits act as predictors of a 
dementing process in PD [1, 9, 10], in which dementia has been said to be largely due 
to an age-dependent and tau-dependent posterior cortically based process, rather than 
a dopaminergic dysfunction in frontostriatal networks [10]. In sum, our results indicate 
that the MMSE can reflect the global atrophy present in medium to long duration PD, 
but has poor power to detect these changes in bilateral temporo-parietal regions. In 
contrast, the specific regional posterior correlates of the pentagon copying test 
correspond to the differences in CTh between patients and controls. Our study has 
some limitations. There is currently no generally accepted standard for in vivo cortical 
thickness measurements, because in vivo reference values of cortical thickness or 
systematic comparison of post mortem data with an in vivo estimation are not available 
[27]. However, studies regarding which method best monitors cerebral involution in PD 
have exhibited that surface-based methods, especially CTh, are sensitive to PD-related 
neural degeneration [28]. 
Another limitation of our study is the lack of previous information about the reliability of 
the scoring systems used. However, Ala et al., [29], applying the original scoring 
system of the pentagon’s item, reported high inter-raters reliability (Cronbach’s α: 0.98). 
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Finally, our results cannot be generalized to all the pre-dementia stages of PD, 
because our sample of patients had a relatively long duration of disease, thus they are 
not representative of early stages. 
In summary, our study suggests that both MMSE and the pentagon item reflect global 
brain degeneration that at a regional level is mainly located in the posterior regions, but 
the pentagon copying test correlated with more areas and with bigger cluster sizes. Our 
data supports the utility of the pentagon’s item as a tool in patient care to monitor 
evolution of cognitive status. 
There are previous studies that have independently addressed the value of the 
pentagon item [1, 9, 10] and cortical thinning [30] as markers for cognitive decline or 
dementia. However, to our knowledge there are no previous studies analyzing in the 
same sample the predictive power of cortical thickness and pentagon’s item to predict 
future dementia in individual patients. Future longitudinal studies are needed to 
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Figure 1. CTh differences between A) patients and healthy controls (Healthy controls > 
PD patients) and B) patients with correct or incorrect pentagon according to the original 
grading criteria used in the MMSE. Monte-Carlo Null Z Simulations at corrected 
p<0.05. Color bar indicates the level of statistical significance 
Figure 2. CTh areas showing significant correlations in PD patients with A) MMSE, B) 
Pentagon item scored according to 3MS system and C) Pentagon item scored 
according to the simple scoring system. Monte-Carlo Null Z Simulations at p<0.05. 
Color bar indicates the level of statistical significance 
Figure S1. Drawing and grading scores examples of patients’ pentagon copying test.  
 
 





ta, χb p value 
Age 64 ± 11.1 63.4 ± 10.5 .287a .775 
Sex 
(male/female) 37/55 19/17 .521
b .300 
Education, 
years 10.6 ±  5.4 11.4 ±  4.3 .750
a .454 
Age at onset 56 ± 12.2    
Evolution, 







   
UPDRS-III 16.4 ± 9.3    
LEDD 803.7 ± 494.2    
UPDRS-III: Unified Parkinson’s Disease Rating Scale-III; H&Y: Hoehn & Yahr; LEDD: Levodopa Equivalent Daily 
Dose. Values are mean ± Standard Deviation (SD); aStudent t test statistics; bχ2 statistics 
 
 
Table 2. Differences between PD patients and healthy subjects in global atrophy measures and correlations 
between cognitive status and pentagon item and atrophy measures 
 Group differences Correlations in PD patients 
PD Patients Controls 
ta/F p 
MMSE 3MS WG-A 
Mean SD Mean SD r p r p ρ p 
Mean CTh* 2.4 0.1 2.5 0.1 2.610a 0.010 0.251 0.016 0.224 0.033 0.958 <0.0001 
Cortical GMV** 601.55 64.2 611.62 54.3 2.027 0.157 0.189 0.075 0.279 0.008 0.185 0.082 
LVV** 25.2 14.3 20.0 8.4 4.219 0.042 0.222 0.035 0.179 0.063 0.179 0.063 
 
CTh: Cortical Thickness; LVV: Lateral Ventricular Volume; GMV: Gray Matter Volume; SD: Standard Deviation; 
MMSE: Mini-Mental State Examination; 3MS: Modified Mini-Mental State; WG: simple scoring system used by 
Williams-Gray et al. (2007-2013), modified from Ala et al. (2001). t: Student t test statistics; F: ANCOVA (ICV 
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Talairach coordenates of 
the maxima 
Z value Clusterwise 
probability 
X Y Z 
Left Supramarginal 8006.70 -48.6 -48.8 37.3 -4.682 0.0001 
Fusiform 3503.77 -26.6 -51.0 -10.0 -3.536 0.0001 
Right Superior parietal 112522.39 26.8 -56.9 43.1 -4.420 0.0001 
Results were corrected using family wise error correction with Monte Carlo Null-Z Simulation and 
thresholded at p=.05 
Table S2. Significant clusters showing differences between patients with acceptable or incorrect 










X Y Z 
L Superior temporal 3236.85 -46.4 -31.4 5.5 -4.057 .0001 
L Precuneus 4220.40 -13.9 -39.7 33.5 -3.369 .0001 
R Postcentral 8607.50 26.8 -25.5 48.0 -3.493 .0001 
R Superior parietal 2792.71 30.9 -39.0 40.6 -3.271 .0003 
R Posterior cingulate 2165.76 5.7 -29.4 34.9 -3.001 .005 
R Precentral 1515.57 47.9 5.6 27.5 -2.363 .0464 
L: Left; R: Right 
 






Talairach coordenates of 




probability X Y Z 
MMSE  L Lateral occipital 1646.00 -27.7 -83.0 4.4 2.965 .0237 
L Isthmus cingulate 2194.28 9.6 -49.9 8.5 2.365 .0034 
3MS L Inferior parietal 2133.70 -47.7 -61.0 12.7 4.649 .0056 
L Precuneus 3544.58 -9.3 -55.2 28.9 3.839 .0001 
L Superior temporal 1565.52 -48.2 -31.5 6.4 3.824 .0344 
L Fusiform 1700.77 -32.8 -44.6 -10.0 3.626 .0208 
L Paracentral 2292.86 -13.0 -11.9 42.2 2.810 .0208 
R Superior temporal 11309.12 50.0 -33.5 14.9 5.318 .0001 
R Fusiform 2097.70 29.0 -66.0 -3.2 3.538 .006 





L Precuneus 2322.96 -7.8 -43.0 45.0 2.759 .0028 
R Supramarginal 6373.23 56.1 -23.4 35.9 3.750 .0001 
R Superior parietal 2001.60 35.4 -44.2 57.6 3.600 .0076 
R Fusiform 1502.36 29.1 -66.4 -4.1 2.589 .0477 
R Posterior cingulate 1888.19 5.5 -29.9 36.0 2.304 .0116 
MMSE: Mini-Mental State Examination; 3MS: Modified Mini-Mental State; L: Left; R: Right 
 
 

